Cargando…

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women

PURPOSE: To assess the prevalence of KRAS, BRAF, and TP53 mutations in cases of low-grade and high-grade serous carcinomas and to evaluate the clinical outcomes of these morphologically distinct carcinomas. MATERIALS AND METHODS: Patients with primary invasive serous carcinomas were classified accor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Yun-Hyun, Kim, Dae-Yeon, Kim, Jong-Hyeok, Kim, Yong-Man, Kim, Kyu-Rae, Nam, Joo-Hyun, Kim, Young-Tak
Formato:	Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678703/ https://www.ncbi.nlm.nih.gov/pubmed/19430562 http://dx.doi.org/10.3349/ymj.2009.50.2.266

Ejemplares similares

Peritoneal Carcinosarcoma and Ovarian Papillary Serous Carcinoma Are the Same Origin: Analysis of TP53 Mutation and Microsatellite Suggests a Monoclonal Origin
por: Woo, Chang Gok, et al.
Publicado: (2014)

Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer
por: Park, Yu Ran, et al.
Publicado: (2018)

The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience
por: Lee, Young-Jae, et al.
Publicado: (2017)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy
por: Kwon, Yong Soon, et al.
Publicado: (2009)

Impact of body mass index on the prognosis of Korean women with endometrioid adenocarcinoma of the uterus: A cohort study
por: Park, Jeong-Yeol, et al.
Publicado: (2014)

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas
por: Sundov, Dinka, et al.
Publicado: (2013)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma
por: Baek, Min-Hyun, et al.
Publicado: (2018)

Analysis and Comparison of Somatic Mutations in Paired Primary and Recurrent Epithelial Ovarian Cancer Samples
por: Kim, Yong-Man, et al.
Publicado: (2014)

Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma
por: Kang, Hyo Jeong, et al.
Publicado: (2013)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

The efficacy of sentinel lymph node mapping with indocyanine green in cervical cancer
por: Kim, Ju-Hyun, et al.
Publicado: (2018)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

Laparoendoscopic single-site versus conventional laparoscopic surgery for ovarian mature cystic teratoma
por: Park, Jeong-Yeol, et al.
Publicado: (2015)

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53
por: Viros, Amaya, et al.
Publicado: (2014)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome
por: Park, Kyoung-Jin, et al.
Publicado: (2016)

KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions
por: Nakamura, Kohei, et al.
Publicado: (2016)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

The association between expression of p53 and aggressiveness of serous adenocarcinoma of the uterine cervix
por: Lee, Sul, et al.
Publicado: (2020)

Accuracy of frozen section diagnosis and factors associated with final pathological diagnosis upgrade of mucinous ovarian tumors
por: Park, Jeong-Yeol, et al.
Publicado: (2019)

Reproductive outcomes after laparoscopic radical trachelectomy for early-stage cervical cancer
por: Park, Jeong-Yeol, et al.
Publicado: (2014)

Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: a single institute experience
por: Lee, Young-Jae, et al.
Publicado: (2017)

Feasibility and Safety of Laparoscopic Surgery for Obese Korean Women with Endometrial Cancer: Long-Term Results at a Single Institution
por: Baek, Min-Hyun, et al.
Publicado: (2014)

The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study
por: Kim, Tae-Woo, et al.
Publicado: (2023)

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
por: Mota, Alba, et al.
Publicado: (2015)

Feasibility and safety of fertility-sparing surgery in epithelial ovarian cancer with dense adhesion: a long-term result from a single institution
por: Baek, Min-Hyun, et al.
Publicado: (2020)

KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis
por: Du, Lijun, et al.
Publicado: (2017)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Trends in treatment during the last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy: a comparative analysis of 10-year data in a single institution
por: Jang, Tae-Kyu, et al.
Publicado: (2018)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
por: Won, Daeyoun David, et al.
Publicado: (2017)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease
por: Lee, Young-Jae, et al.
Publicado: (2017)

Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma
por: Kim, Yong-Man, et al.
Publicado: (2018)

Increased interleukin-6 and TP53 levels in rotator cuff tendon repair patients with hypercholesterolemia
por: Yoon, Jong Pil, et al.
Publicado: (2022)

TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
por: Lee, Eung Bae, et al.
Publicado: (2010)

Serous Carcinoma of the Endometrium with Mesonephric-Like Differentiation Initially Misdiagnosed as Uterine Mesonephric-Like Adenocarcinoma: A Case Report with Emphasis on the Immunostaining and the Identification of Splice Site TP53 Mutation
por: Choi, Sangjoon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0drdd3e06e61rm55rqb87hd18q